Improving the prediction of medication compliance: The example of bisphosphonates for osteoporosis

Medical Care

Volumn 47, Issue 3, 2009, Pages 334-341

  Curtis, Jeffrey R ^a,b,d   Xi, Juan ^a   Westfall, Andrew O ^a   Cheng, Hong ^a   Lyles, Kenneth ^c   Saag, Kenneth G ^a,b   Delzell, Elizabeth ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b University of Alabama at Birmingham   (United States)

^c DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d The University of Alabama at Birmingham   (United States)

Author keywords

Adherence; Bisphosphonate; Compliance; Osteoporosis

Indexed keywords

ALENDRONIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIGLAUCOMA AGENT; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTROGEN; GLUCOCORTICOID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; SEROTONIN UPTAKE INHIBITOR; THIAZIDE DIURETIC AGENT; ANTILIPEMIC AGENT; BONE DENSITY CONSERVATION AGENT;

ADULT; AGED; ARTICLE; COLONOSCOPY; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DIABETES MELLITUS; FEMALE; GENDER; GLAUCOMA; HEALTH CARE UTILIZATION; HIP FRACTURE; HUMAN; HYPERTENSION; HYPERTHYROIDISM; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MAMMOGRAPHY; OCCULT BLOOD; OSTEOPOROSIS; PATIENT COMPLIANCE; PREDICTION; RHEUMATOID ARTHRITIS; SIGMOIDOSCOPY; SMOKING; VERTEBRA FRACTURE; AGE; CHRONIC DISEASE; HEALTH INSURANCE; INSURANCE; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PREVENTIVE HEALTH SERVICE; PSYCHOLOGICAL ASPECT; SEX DIFFERENCE; STATISTICAL MODEL; STATISTICS; UNITED STATES; UTILIZATION REVIEW;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; ANTIDEPRESSIVE AGENTS; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BONE DENSITY CONSERVATION AGENTS; CHRONIC DISEASE; COMORBIDITY; DIPHOSPHONATES; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSURANCE CLAIM REVIEW; INSURANCE, PHARMACEUTICAL SERVICES; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS; PREVENTIVE HEALTH SERVICES; SEX FACTORS; UNITED STATES;

EID: 61849096094     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e31818afa1c     Document Type: Article

References (29)

1. Penning-van Beest FJ, Erkens JA, Olson M, et al. Loss of treatment benefit due to low compliance with bisphosphonate therapy. Osteoporos Int. 2008;19:511-517.
2. Weycker D, Macarios D, Edelsberg J, et al. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int. 2006;17:1645-1652.
3. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81:1013-1022.
4. Rossini M, Bianchi G, Di Munno O, et al. Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int. 2006;17: 914-921.
5. Penning-van Beest FJ, Goettsch WG, Erkens JA, et al. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis. Clin Ther. 2006;28:236-242.
6. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922-928.
7. Gold DT, Silverman S. Review of adherence to medications for the treatment of osteoporosis. Curr Osteoporos Rep. 2006;4:21-27.
8. Lo JC, Pressman AR, Omar MA, et al. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int. 2006; 17:922-928.
9. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414-2419.
10. Caro JJ, Salas M, Speckman JL, et al. Persistence with treatment for hypertension in actual practice. CMAJ. 1999;160:31-37.
11. Rizzo JA, Simons WR. Variations in compliance among hypertensive patients by drug class: implications for health care costs. Clin Ther. 1997;19:1446-1457; discussion 1424-1425.
12. Parris ES, Lawrence DB, Mohn LA, et al. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care. 2005;28:595-599,
13. Perreault S, Lamarre D, Blais L, et al. Persistence with treatment in newly treated middle-aged patients with essential hypertension. Ann Pharmacother. 2005;39:1401-1408.
14. Gibson TB, Mark TL, McGuigan KA, et al. The effects of prescription drug copayments on statin adherence. Am J Manag Care. 2006;12:509-517.
15. Curtis JR, Westfall AO, Allison JJ, et al. Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users. Osteoporos Int. 2006;17:1268-1274.
16. Brookhart MA, Patrick AR, Dormuth C, et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect. Am J Epidemiol. 2007;166:348-354.
17. Briesacher B, Andrade S, Fouayzi H, et al. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy. 2008;28:437-443.
18. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986; 24:67-74.
19. Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther. 2004;26:245-256.
20. Sikka R, Xia F, Aubert RE. Estimating medication persistency using administrative claims data. Am J Manag Care. 2005;11:449-457.
21. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
22. Curtis JR, Westfall AO, Cheng H, et al. The benefit of adherence with bisphosphonates depends on age and fracture type: results from an analysis of 101,038 new bisphosphonate users. J Bone Miner Res. 2008;23:1435-1441.
23. Hosmer JDW, Lemeshow S. Applied Logistic Regression. 2nd ed. New York, NY: John Wiley and Sons; 2000.
24. Lemeshow S, Hosmer DW Jr. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol. 1982;115:92-106.
25. Clowes JA, Peel NF, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004; 89:1117-1123.
26. Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92:1296-1304.
27. Brookhart MA, Patrick AR, Schneeweiss S, et al. Physician follow-up and provider continuity are associated with long-term medication adherence: a study of the dynamics of statin use. Arch Intern Med. 2007;167: 847-852.
28. Greenland S. An introduction to instrumental variables for epidemiologists. Int J Epidemiol 2000;29:722-729.
29. Angrist J, Imbens G, Rubin D. Identification of causal effects using instrumental variables. J Am Stat Assoc. 1996;81:444-455.